

,
:

,2013

ABSTRACT

The goal of this thesis is to study the relationship of the elderly with their skin and its cosmetic care. Furthermore it explores how the seniors are affected when provided with facial aesthetic treatments.

Questionnaires were used for this purpose, which were filled in by members of the KAPI, that is under the jurisdiction of the municipality of Neapolis – Sykeon, immediately after moisturizing treatment was applied.

The conclusions that were drawn allow us to examine from different standpoints how an aesthetic treatment affects the everyday life of an elderly person regardless if there is in fact a visible enchantment of their skin after the treatment is applied to them.

In addition, the research focuses on the peculiarities of the structure that skin presents over time, as well as how rapidly cosmetic products and esthetic machines advance and develop.

| | | | |
|-------|----------|-----------|----|
| | μ | | 1 |
| | | | 2 |
| | 1: | μ | 3 |
| 1.1 | | μ μ | 3 |
| 1.2 | | μ | 4 |
| 1.3 | μ | | 4 |
| 1.4 | | μ | 5 |
| 1.5 | μ | | 6 |
| 1.6 | | μ | 6 |
| 1.7 | | μ | 7 |
| 1.7.1 | | μ | 7 |
| 1.7.2 | | | 7 |
| 1.7.3 | | μ | 8 |
| 1.8 | | μ | 9 |
| 1.8.1 | μ μ | | 9 |
| 1.8.2 | | | 10 |
| 1.9 | μ μ | | 10 |
| 1.9.1 | | | 11 |
| 1.9.2 | | | 12 |
| 1.10 | – | μ | 12 |
| 1.11 | μ | | 14 |
| | 2: | μ | 16 |
| 2.1 | μ : | | 16 |
| 2.2 | | μ | 17 |
| 2.3 | μ | μ | 18 |
| 2.4 | | μ | 18 |
| 2.4.1 | | μ | 19 |
| 2.4.2 | | | 20 |
| 2.4.3 | | | 21 |
| 2.5 | | μ μ | 22 |
| 2.6 | | μ | 25 |
| 2.6.1 | μ | | 25 |

| | | |
|--------|-------------|----|
| 2.6.2 | | 27 |
| 2.6.3 | | 27 |
| 2.6.4 | | 27 |
| 2.6.5 | | 28 |
| 2.6.6 | , | 28 |
| 2.6.7 | | 28 |
| 2.6.8 | | 29 |
| 2.6.9 | | 29 |
| 2.6.10 | μ | 29 |
| 2.6.11 | | 30 |
| 3 : | μ | 31 |
| 3.1 | μ | 31 |
| 3.1.1 | | 31 |
| 3.1.2 | DNA | 32 |
| 3.1.3 | μ - μ | 32 |
| 3.1.4 | | 33 |
| 3.1.5 | | 33 |
| 3.1.6 | μ | 34 |
| 3.1.7 | | 35 |
| 3.1.8 | μ | 35 |
| 3.1.9 | | 36 |
| 3.1.10 | | 37 |
| 3.2 | μ μ | 37 |
| 3.2.1 | μ | 37 |
| 3.2.2 | ()..... | 39 |
| 3.2.3 | | 42 |
| 3.3 | μ | 44 |
| 3.3.1 | μ μ | 45 |
| 3.2 | μ μ μ | 47 |
| 3.2.1 | μ μ | 48 |
| 3.2.2 | μ μ | 48 |
| 3.2.3 | μ μ | 49 |
| 4 : | | 50 |

| | | |
|-------|-----------|----|
| 4.1 | | 50 |
| 4.1.2 | | 50 |
| 4.2 | μ | 50 |
| 4.3 | μ μ | 65 |
| 4.4 | | 66 |
| | | 68 |
| μ 1. | μ | 70 |

2 : μ

, μ , μ .(4) , μ



2.1 μ :

μ . μ DNA, μ . μ .(4)

2.3

μ

μ

μ

μ

:

μ

-

1.

2.

μ

3.

μ

4.

μ

5.

6.

μ

7.

μ

μ

8.

, μ

μ

9.

μ

μ

μ

μ

μ

.(4,18)

μ

2.4

μ

.

,

μ

,

μ

,

μ

μ

μ

,

μ

μ

μ

.

.(4,19)

2.6

μ

2.6.1 μ

μ

μ

μ μ

μ

μ

μ

μ μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ

μ μ

μ

.(4,15)

μ

μ

μ

μ μ

μ

μ

μ

μ

μ

μ

,

μ

1%

μ

μ μ ,

.

,

μ

μ

,

,

μ

μ

,

.

μ μ

μ

μ

,

μ

,

μ μ μ

.(4,15)

μ

μ

μ

70

.

μ

,

μ

μ

μ

μ

μ

μ ,

μ

μ

.

μ

μ

μ ,

2.6.11

➤ μ μ , μ μ μ .
 μ μ , μ μ .

➤ μ μ μ μ . , μ .

➤ μ μ μ (

➤ μ μ μ , μ .
 μ μ μ . 75

➤ μ μ μ , μ ,
 μ μ μ , μ μ μ μ .
 μ μ 40 μ μ 65, .(15)

μ , μ μ , μ μ .(4)

2. μ μ μ .

:

- μ μ , μ , μ .
- μ .
- μ .
- μ μ μ .

μ :

μ . μ μ μ μ μ μ μ μ .

1. μ μ .

2. μ μ μ 10 μ .

3. μ μ μ vapozone.

4. μ , , μ +, 1-3 mA, μ μ . μ μ 4-6 .

5. μ μ .

6. μ μ μ .


7. μ .

8. , μ μ μ .

μ (, μ , μ , μ) : μ , .(4)


| | Frequency | Percent | Valid Percent | Cumulative Percent |
|-------|-----------|---------|---------------|--------------------|
| Valid | <u>96</u> | 96,0 | 96,0 | 96,0 |
| | 4 | 4,0 | 4,0 | 100,0 |
| Total | 100 | 100,0 | 100,0 | |

διάθεση



μ , 96% μ , 97%

Πρώτη θεραπεία




| | Frequency | Percent | Valid Percent | Cumulative Percent |
|------------------|-----------|---------|---------------|--------------------|
| Valid NAI | 64 | 64,0 | 64,0 | 64,0 |
| | 36 | 36,0 | 36,0 | 100,0 |
| Total | 100 | 100,0 | 100,0 | |

1

.....


| | Frequency | Percent | Valid Percent | Cumulative Percent |
|-------|-----------|---------|---------------|--------------------|
| Valid | 78 | 78,0 | 78,0 | 78,0 |
| | 22 | 22,0 | 22,0 | 100,0 |
| Total | 100 | 100,0 | 100,0 | |

1η επίσκεψη



64% μ
, 78% μ μμ
μμ .



Δέρμα μετά τη θεραπεία



μ
μ μ : 37%
μ , 31% μ ,
30% μ 2% μ
.

* μ μ

| Count | μ μ | | | | Total |
|-------|-----|----|----|----|-------|
| | μ | μ | μ | μ | |
| NAI | 0 | 26 | 22 | 16 | 64 |
| | 2 | 11 | 8 | 15 | 36 |
| Total | 2 | 37 | 30 | 31 | 100 |




μ

| | Frequency | Percent | Valid Percent | Cumulative Percent |
|-------|-----------|---------|---------------|--------------------|
| Valid | 2 | 2,0 | 2,0 | 2,0 |
| | 98 | 98,0 | 98,0 | 100,0 |
| Total | 100 | 100,0 | 100,0 | |

| | Frequency | Percent | Valid Percent | Cumulative Percent |
|------------|-----------|---------|---------------|--------------------|
| Valid | 2 | 2,0 | 100,0 | 100,0 |
| Missing 99 | 98 | 98,0 | | |
| Total | 100 | 100,0 | | |

μ μ 2% μ μ μ

Χρησιμοποιείτε καλλυντικά προϊόντα στο σπίτι;




76%, μμ ,
μ .

* μ ;

Count


| | μ | | Total |
|-------|----|----|-------|
| | | ; | |
| 58-64 | 24 | 10 | 34 |
| 65-69 | 26 | 6 | 32 |
| 70-74 | 20 | 5 | 25 |
| 75+ | 6 | 3 | 9 |
| Total | 76 | 24 | 100 |



μ μ μ μ μ

, 65 69 .

Φροντίδα μετά τη θεραπεία



μ . μ μ μ μ μ .

82%

μ .

| | Frequency | Percent | Valid Percent | Cumulative Percent |
|-------|-----------|---------|---------------|--------------------|
| Valid | 42 | 42,0 | 42,0 | 42,0 |
| | 58 | 58,0 | 58,0 | 100,0 |
| Total | 100 | 100,0 | 100,0 | |

μ , μ 42% μ μ

| | Frequency | Percent | Valid Percent | Cumulative Percent |
|-------|-----------|---------|---------------|--------------------|
| Valid | 53 | 53,0 | 53,0 | 53,0 |
| | 47 | 47,0 | 47,0 | 100,0 |
| Total | 100 | 100,0 | 100,0 | |

μ μ 53% μ μ

| | Frequency | Percent | Valid Percent | Cumulative Percent |
|-------|-----------|---------|---------------|--------------------|
| Valid | 43 | 43,0 | 43,0 | 43,0 |
| | 57 | 57,0 | 57,0 | 100,0 |
| Total | 100 | 100,0 | 100,0 | |

μ 43% μ μ .

| | Frequency | Percent | Valid Percent | Cumulative Percent |
|-------|-----------|---------|---------------|--------------------|
| Valid | 16 | 16,0 | 16,0 | 16,0 |
| | 84 | 84,0 | 84,0 | 100,0 |
| Total | 100 | 100,0 | 100,0 | |

μ . 16% μ μ

| | Frequency | Percent | Valid Percent | Cumulative Percent |
|-------|-----------|---------|---------------|--------------------|
| Valid | 13 | 13,0 | 13,0 | 13,0 |
| | 87 | 87,0 | 87,0 | 100,0 |
| Total | 100 | 100,0 | 100,0 | |

μ 13% μ μ .
3% μ μ .

| | Frequency | Percent | Valid Percent | Cumulative Percent |
|-------|-----------|---------|---------------|-----------------------|
| Valid | 100 | 100,0 | 100,0 | 100,0 |

μ , , μ

1. , . (2004). μ : INTERBOOKS.
2. μμ , . - . :
3. μ μ (2002). 2. :
4. , . (2002). 3. :
5. , . (1998). μ 1. :
6. , . (2002). μ 2. :
7. , . (2006). μ 3. :
8. , . (2001). μ 1. :
9. , . (2008). μ 3. :
10. , . (2010). . :
UNIVERSITY STUDIO PRESS.
11. μ , . (2007). μ . :
GM Design.
12. , . (2009, 2 μ). μ
27, (5), 742-752.
13. , .. , .
, 53(2), 183-189, 1988
14. http://www.plastikos.gr/plastikos/your_skin_type.php
15. <http://www.ygeianews.gr/section/good-life/content/ti-sumbainei-otan-gername>
16. http://www.iatronet.gr/article.asp?art_id=6231 , ,
μ
17. http://www.medlook.net.cy/article.asp?item_id=2833
18. http://www.medlook.net.cy/article.asp?item_id=424
19. http://www.aisthitikisimera.gr/index.php?option=com_content&view=article&id=47:elaia2&catid=1:latest-news&Itemid=72
20. <http://www.mayoclinic.com/health/wrinkle-creams/SN00010>

21. <http://www.iatrotek.org/ioArt.asp?id=17396> , , , , ,
22. <http://www.ideeaf.gr/files/Giransoi-tou-dermatos-sigxronoi-tropoi-antimetopisis.pdf>
23. <http://www.mybeautynet.gr/reymata-galvaniko-ypsisyhna-faradiko/aisthitiki-therapeia-me-galvaniko-i-synehes-reyma-vasikes>

μ 1. μ

1) : 58-64 65-69 70-74 75+

2) ;

3) μ ;

4) ;

5) ;

6) μ μ : μ μ

7) μ μ ;
, ;

8) μ ;

9) μ :

10) μ ;

, ;

μ μ
 μ

μ

11)

μ ;

12)

μ

.

!!!